Bevacizumab inhibits breast cancer-induced osteolysis, surrounding soft tissue metastasis, and angiogenesis in rats as visualized by VCT and MRI.

The aim of this study was to evaluate the effect of an antiangiogenic treatment with the vascular endothelial growth factor antibody bevacizumab in an experimental model of breast cancer bone metastasis and to monitor osteolysis, soft tissue tumor, and angiogenesis in bone metastasis noninvasively by volumetric computed tomography (VCT) and magnetic resonance imaging (MRI). After inoculation of MDA-MB-231 human breast cancer cells into nude rats, bone metastasis was monitored with contrast-enhanced VCT and MRI from day 30 to day 70 after tumor cell inoculation, respectively. Thereby, animals of the treatment group (10 mg/kg bevacizumab IV weekly, n = 15) were compared with sham-treated animals (n = 17). Treatment with bevacizumab resulted in a significant difference versus control in osteolytic as well as soft tissue lesion sizes (days 50 to 70 and 40 to 70 after tumor cell inoculation, respectively; P < .05). This observation was paralleled with significantly reduced vascularization in the treatment group as shown by reduced increase in relative signal intensity in dynamic contrast-enhanced MRI from days 40 to 70 (P < .05). Contrast-enhanced VCT and histology confirmed decreased angiogenesis as well as new bone formation after application of bevacizumab. In conclusion, bevacizumab significantly inhibited osteolysis, surrounding soft tissue tumor growth, and angiogenesis in an experimental model of breast cancer bone metastasis as visualized by VCT and MRI.

[1]  T. Shih,et al.  Blood perfusion of vertebral lesions evaluated with gadolinium‐enhanced dynamic MRI: In comparison with compression fracture and metastasis , 2002, Journal of magnetic resonance imaging : JMRI.

[2]  F. Montemurro,et al.  Dynamic contrast enhanced magnetic resonance imaging in monitoring bone metastases in breast cancer patients receiving bisphosphonates and endocrine therapy , 2004, Acta radiologica.

[3]  Wolfhard Semmler,et al.  Dynamic contrast-enhanced magnetic resonance imaging rapidly indicates vessel regression in human squamous cell carcinomas grown in nude mice caused by VEGF receptor 2 blockade with DC101. , 2004, Neoplasia.

[4]  Wolfhard Semmler,et al.  Small Animal Computed Tomography Imaging , 2007 .

[5]  R. Coleman.  Skeletal complications of malignancy , 1997, Cancer.

[6]  Napoleone Ferrara,et al.  VEGF and the quest for tumour angiogenesis factors , 2002, Nature Reviews Cancer.

[7]  Ivo Que,et al.  Optical imaging of cancer metastasis to bone marrow: a mouse model of minimal residual disease. , 2002, The American journal of pathology.

[8]  E. Perez,et al.  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.

[9]  F. Orr,et al.  The effect of Neovastat (AE-941) on an experimental metastatic bone tumor model. , 2002, International journal of oncology.

[10]  J. Chirgwin,et al.  Transforming growth factor-beta in osteolytic breast cancer bone metastases. , 2003, Clinical orthopaedics and related research.

[11]  R. Bachelier,et al.  Advances in optical imaging and novel model systems for cancer metastasis research , 2007, Clinical & Experimental Metastasis.

[12]  M. Chávez-MacGregor,et al.  Angiogenesis in the Bone Marrow of Patients with Breast Cancer , 2005, Clinical Cancer Research.

[13]  M. Birch,et al.  Vascular endothelial growth factor acts as an osteolytic factor in breast cancer metastases to bone , 2005, British Journal of Cancer.

[14]  R. D. Hunter,et al.  WHO Handbook for Reporting Results of Cancer Treatment , 1980 .

[15]  Thiennu H. Vu,et al.  Matrix Metalloproteinase 9 and Vascular Endothelial Growth Factor Are Essential for Osteoclast Recruitment into Developing Long Bones , 2000, The Journal of cell biology.

[16]  L R Schad,et al.  Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. , 1991, Journal of computer assisted tomography.

[17]  G. Sledge,et al.  A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. , 2003, Seminars in oncology.

[18]  F. Kiessling,et al.  Characterization of a rat model with site‐specific bone metastasis induced by MDA‐MB‐231 breast cancer cells and its application to the effects of an antibody against bone sialoprotein , 2005, International journal of cancer.

[19]  P Kelly Marcom,et al.  Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  S. Nishikawa,et al.  Vascular Endothelial Growth Factor Can Substitute for Macrophage Colony-Stimulating Factor in the Support of Osteoclastic Bone Resorption , 1999, The Journal of experimental medicine.

[21]  R. Rubens,et al.  Assessment of response to therapy in advanced breast cancer. , 1977, British Journal of Cancer.

[22]  D. Chappard,et al.  Rat Models of Bone Metastases , 2006, Clinical & Experimental Metastasis.

[23]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[24]  Fabian Kiessling,et al.  Non-invasive assessment of vessel morphology and function in tumors by magnetic resonance imaging , 2007, European Radiology.

[25]  Wolfhard Semmler,et al.  Retrospective Motion Gating in Small Animal CT of Mice and Rats , 2007, Investigative radiology.

[26]  S. Obenauer,et al.  Flat-panel detector-based volume computed tomography: a novel 3D imaging technique to monitor osteolytic bone lesions in a mouse tumor metastasis model. , 2007, Neoplasia.

[27]  H. Redmond,et al.  TGFβ-1 regulation of VEGF production by breast cancer cells , 1997, Annals of Surgical Oncology.

[28]  S. Rafii,et al.  The vascular endothelial growth factor receptor (VEGFR‐1) supports growth and survival of human breast carcinoma , 2006, International journal of cancer.

[29]  E. Smit,et al.  Design of clinical trials of radiation combined with antiangiogenic therapy. , 2007, The oncologist.

[30]  Sheng-Kwei Song,et al.  MRI Detection of Early Bone Metastases in B16 Mouse Melanoma Models , 2005, Clinical & Experimental Metastasis.

[31]  G. Edelstyn,et al.  The radiological demonstration of osseous metastases. Experimental observations. , 1967, Clinical radiology.

[32]  Geoff J M Parker,et al.  Imaging Tumor Vascular Heterogeneity and Angiogenesis using Dynamic Contrast-Enhanced Magnetic Resonance Imaging , 2007, Clinical Cancer Research.

[33]  Wolfhard Semmler,et al.  Potential applications of flat-panel volumetric CT in morphologic and functional small animal imaging. , 2005, Neoplasia.

[34]  Napoleone Ferrara,et al.  Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. , 2005, Cancer research.

[35]  B. Olsen,et al.  Multiple roles of vascular endothelial growth factor (VEGF) in skeletal development, growth, and repair. , 2005, Current topics in developmental biology.

[36]  L. Schad,et al.  Dynamic T1‐weighted monitoring of vascularization in human carcinoma heterotransplants by magnetic resonance imaging , 2003, International journal of cancer.

[37]  P. Clézardin,et al.  Angiostatin Inhibits Bone Metastasis Formation in Nude Mice through a Direct Anti-osteoclastic Activity* , 2003, Journal of Biological Chemistry.

[38]  H. Vloedgraven,et al.  Monitoring Metastatic Behavior of Human Tumor Cells in Mice with Species‐Specific Polymerase Chain Reaction: Elevated Expression of Angiogenesis and Bone Resorption Stimulators by Breast Cancer in Bone Metastases , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[39]  T. Kalebic,et al.  Association of 12 serum biochemical markers of angiogenesis, tumour invasion and bone turnover with bone metastases from breast cancer: a crossectional and longitudinal evaluation , 2006, British Journal of Cancer.

[40]  Wolfhard Semmler,et al.  Volumetric computed tomography (VCT): a new technology for noninvasive, high-resolution monitoring of tumor angiogenesis , 2004, Nature Medicine.

[41]  G. Mundy.  Metastasis: Metastasis to bone: causes, consequences and therapeutic opportunities , 2002, Nature Reviews Cancer.